Trials / Unknown
UnknownNCT04194684
Nab-Paclitaxel in Patients With ER+/HER2- Recurrent Metastatic Breast Cancer
Nab-Paclitaxel in Patients With ER+/HER2- Recurrent Metastatic Breast Cancer：a Multi-center Study
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 108 (estimated)
- Sponsor
- Chinese Academy of Medical Sciences · Academic / Other
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study is a single-arm, open, multi-center clinical study of nab-paclitaxel as the therapy ER+/HER2- recurrent metastatic breast cancer。
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | nab-paclitaxel | nab-paclitaxel 125mg / m2, intravenous drip 30min, d1, 8, 21 days as a cycle, until the disease progresses or intolerable toxicity. According to the calculation results, the administered dose can be within ± 10% of the calculated dose. |
Timeline
- Start date
- 2019-12-28
- Primary completion
- 2022-12-28
- Completion
- 2023-01-30
- First posted
- 2019-12-11
- Last updated
- 2019-12-11
Source: ClinicalTrials.gov record NCT04194684. Inclusion in this directory is not an endorsement.